News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  5th August 2013  
  Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells
 
 




Authors
Abdul Qader Omer Al-aidaroos1, Hiu Fung Yuen1, Ke Guo1, Shu Dong Zhang2, Tae-Hoon Chung4, Wee Joo Chng3,4, Qi Zeng1,5,*.

1 - Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR),      Singapore.
2 - Center for Cancer Research and Cell Biology, Queen’s University of Belfast, Belfast, United Kingdom.
3 - Haematological Malignancy Genomics Lab, Cancer Science Institute of Singapore, National University      of Singapore, Singapore.
4 - Department of Haematology-Oncology, National University Cancer Institute, Singapore National      University Health System, Singapore.
5 - Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore,      Singapore

* Corresponding author: Zeng QI's lab, please click here.

Published online in the Journal of Clinical Investigation, Vol. 123 (8), on 8 July 2013.
To read the paper, please click here.

For press release, please click here.

Also featured on August cover of the JCI.



Abstract

Metastasis-associated PRL-3 has pleiotropic effects in driving cancer progression, yet the signaling mechanisms of PRL-3 are still not fully understood. Here, we provide evidence for PRL-3-induced hyperactivation of the EGFR and its downstream signaling cascades in multiple human cancer cell lines. Mechanistically, PRL-3-induced activation of EGFR was attributed primarily to transcriptional downregulation of protein tyrosine phosphatase 1B (PTP1B), an inhibitory phosphatase for EGFR. Functionally, PRL-3-induced hyperactivation of EGFR correlated with increased cell growth, pro-migratory character, and tumorigenicity. Importantly, PRL-3 induced cellular addiction to EGFR signaling as evidenced by the pronounced reversion in these oncogenic attributes upon EGFR-specific inhibition. Of clinical significance, we verified elevated PRL-3 expression as a predictive marker for favorable therapeutic response in a heterogeneous colorectal cancer (CRC) patient cohort treated with the clinically-approved anti-EGFR antibody, cetuximab. The identification of PRL-3-driven EGFR hyperactivation and consequential addiction to EGFR signaling opens new avenues for inhibiting PRL-3-driven cancer progression. We propose elevated PRL-3 expression as an important clinical predictive biomarker for favorable anti-EGFR cancer therapy outcome.

Figure Legend:
(Proposed model of PRL-3-induced oncogenic addiction to hyperactivated EGFR. (A-B) Compared to non-PRL-3-overexpressing cells (A), PRL-3 overexpression (B) induces the constitutive hyperactivation of the EGFR primarily via the downregulation of PTP1B, thereby promoting the growth of ‘EGFR-addicted’ cancer cells. (C-D) Compared to non-PRL-3-overexpressing cells (C), such ‘EGFR-addicted’ PRL-3-overexpressing cells (D) are hypersensitive to EGFR inhibition